October 25, 2026 (View All Issues)
Losing Weight and Breast Cancer Risk? The GLP-1 RA Question
The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity and diabetes has sparked interest in their potential effects on breast cancer risk and outcomes. At the 2026 ASCO Annual Meeting, investigators presented several observational studies examining the relationship...
Evolving Strategies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
When diffuse large B-cell lymphoma (DLBCL) fails to respond to front-line treatment or the disease later returns, Jeremy S. Abramson, MD, MMSc, wants to know when the disease progressed, if the patient is eligible for chimeric antigen receptor (CAR) T-cell therapy, and whether or not such treatment ...
TMC-I Regimen May Expand Treatment Access in Advanced Head and Neck Cancer
A lower-cost chemoimmunotherapy approach including oral triple metronomic chemotherapy (TMC) combined with ultra-low-dose immunotherapy termed TMC-I could extend survival for patients with advanced head and neck squamous cell carcinoma in resource-limited countries, according to investigators from...
NCCN Releases New Guideline for Patients and Caregivers: Older Adults With Cancer
The National Comprehensive Cancer Network® (NCCN®) has released a new resource to help patients and caregivers understand how to tailor cancer care for aging populations.
“The medical advances we’ve seen in cardiology and infectious disease are a huge triumph; because we are better at treating...
ASCO 2026: Lung Cancer Specialist Apar Kishor Ganti, MD, Shares His Insights
The 2026 ASCO Annual Meeting featured numerous high-impact studies in lung cancer. To help readers identify the presentations with the greatest potential to influence clinical practice, The ASCO Post asked lung cancer specialist Apar Kishor Ganti, MD, MS, FASCO, to share his top picks. Dr. Ganti is ...
GLP-1 Receptor Agonist Use Linked to Lower Colorectal Cancer Risk in Patients With Inflammatory Bowel Disease
Use of GLP-1 receptor agonist was significantly associated with a lower 5-year incidence of colorectal cancer among patients with inflammatory bowel disease (IBD), including those with concomitant type 2 diabetes, according to findings presented at the 2026 ASCO Breakthrough Meeting in Singapore.1
...
Mocertatug Rezetecan Shows Early Activity in Platinum-Resistant Ovarian and Endometrial Cancers
First results from the global phase I BEHOLD-1 study suggest that the investigational B7-H4–targeted antibody-drug conjugate mocertatug rezetecan showed activity in two difficult-to-treat gynecologic cancers: platinum-resistant ovarian cancer and recurrent or advanced endometrial cancer.1 At the...
New NCCN Survey Highlights Persistent Cancer Drug Shortages
The National Comprehensive Cancer Network® (NCCN®) recently published updated data on the current impact of generic cancer medication shortages in the United States. The data come from survey responses from pharmacy directors and other clinical and administrative leadership at NCCN Member...
